CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer

Abstract

Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks. The data highlights the potential of CX-5461 in overcoming a general mechanism of chemotherapeutic resistance.

Keywords

• ovarian cancer
• parpi
• drug resistance
• cx-5461